Former P
Pakistan
President
Washington, October 31 (ANI): Scientists have found that sound training v
Washington, Oct 31 (ANI): A team of researchers at the Saint Lou
Let's be real. You're here because you're looking for that one exploit, that god-mode cheat that explains how to trick a slot machine to win. But the hard truth?
News in Focus
Geojit Stock Research Team has issued a ‘BUY’ recommendation for Dalmia Bharat, citing robust business fundamentals, sectoral tailwinds, and an attractive valuation window.
Motilal Oswal Financial Services has reiterated a BUY recommendation on Mahindra & Mahindra Financial Services (MMFS), targeting Rs 400 per share—reflecting a potential 15% upside from current
Poonawalla Fincorp, a leading retail lending non-banking financial company, stands at an inflection point and long term investors can get decent returns on this financial services counter.
Axis Securities , through its research division, has issued a compelling BUY recommendation on RITES Limited, the Navratna central public sector enterprise operating under the Ministry of Railways.
Featured, Analyst View, Stock Markets, Banking Sector, Bank of Baroda, Geojit Financial Services, India
Geojit Research has maintained its BUY recommendation on public sector banking major Bank of Baroda (BoB), setting a revised target price of Rs.
Main Regional Stories
Featured, India Business, Analyst View, Bharat Electronics, Geojit Financial Services, India, Public Sector
Geojit Investments Limited has maintained its BUY rating on Bharat Electronics, establishing a formidable 12-month price target of Rs. 504, translating to a compelling 20% upside from current market valuations of Rs. 421.
Motilal Oswal Financial Services has maintained BUY recommendation on automobile major Mahindra & Mahindra with a compelling target price of Rs 4,275—representing an upside potential of 15% from the current market price of Rs
Motilal Oswal Financial Services has reiterated its BUY recommendation on Reliance Industries , with a revised target price of Rs 1,765, implying 16% upside from current levels.
Hem Securities Research has issued a decisive "SUBSCRIBE" recommendation for Sudeep Pharma Limited's initial public offering, valuing the company at a price band of Rs 563-593 per share—representing a P/E multiple exceeding 30x on post-issue annua
